Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 11/20 | 0.56 |
| ▸ | MMP13 | P45452 | 6/20 | 0.46 |
| ▸ | MMP1 | P03956 | 6/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109249 | 0.89 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP2 | |
| Trifluoroacetic Acid SCHEMBL7110999 | 0.84 | ADAM17 (0.55) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7111008 | 0.76 | ADAM17 (0.45) | ADAM17MMP9MMP2MMP3MMP14 | |
| SCHEMBL56831 | 0.75 | MMP1 (0.51) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7107375 | 0.72 | ADAM17 (1.00) | ADAM17MMP13 | |
| SCHEMBL7199642 | 0.72 | MMP13 (0.57) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL460177 | 0.64 | FAAH (0.48) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL10197649 | 0.64 | ADRB3 (0.49) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL10712862 | 0.64 | HTT (0.61) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7208191 | 0.64 | MMP13 (0.80) | MMP13MMP1MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | claimed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | ADAM17 19/4885MMP13 10/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.